Please login to the form below

Not currently logged in
Email:
Password:

New deputy commissioner at US FDA

Robert Califf is a vice chancellor at Duke University

Robert Califf, FDAThe US FDA has named a Duke University vice chancellor as deputy commissioner for medical products and tobacco.

In his new role Dr Robert Califf will help lead the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, the Center for Devices and Radiological Health and the Center for Tobacco Products at the regulator.

He will also oversee the Office of Special Medical Programs in the Office of the Commissioner when he joins in late February.

FDA commissioner Margaret Hamburg, said: “Dr Califf's deep knowledge and experience in the areas of medicine and clinical research will enable the agency to capitalise on, and improve upon, the significant advances we've made in medical product development and regulation over the last few years.”

Dr Califf is the current vice chancellor of clinical and translational research at Duke University in North Carolina in the US. His previous roles at Duke include director of the Duke Translational Medicine Institute (DTMI) and professor of medicine in the Division of Cardiology. He was also founding director of the Duke Clinical Research Institute.

He has previous experience with the FDA serving as a member of the FDA Cardiorenal Advisory Panel and FDA Science Board's Subcommittee on Science and Technology.

29th January 2015

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics